A Dissolvable Eye Insert Loaded With Lactoferrin-Derived Antimicrobial Peptide for Eye Infections

A mucoadhesive freeze-dried ocular insert loaded with human lactoferrin peptide hLF 1-11 provides sustained antimicrobial release for treating infectious keratitis.

Terreni, Eleonora et al.·Biomolecules·2020·Preliminary Evidencein vitro
RPEP-05162In vitroPreliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=not applicable
Participants
Formulation characterization study (no patient population)

What This Study Found

A mucoadhesive freeze-dried insert formulation (HPMC/T2/HA/hLF 1-11) provides sustained release of the lactoferrin-derived antimicrobial peptide with maintained stability.

Key Numbers

6 months chemical stability; 15 months antimicrobial activity; controlled release; HPMC/T2/HA matrix

How They Did This

Formulation development with freeze-dried matrices, characterization of rheology, hydration time, bioadhesion, drug content, and in vitro release profiles.

Why This Research Matters

Infectious keratitis is the leading cause of blindness worldwide, and bacterial resistance makes alternative treatments urgent. An AMP-loaded eye insert avoids the compliance issues of frequent eye drops.

The Bigger Picture

Combining antimicrobial peptides with advanced drug delivery solves two problems at once: bacterial resistance and patient compliance with eye drop regimens.

What This Study Doesn't Tell Us

In vitro characterization only. No antimicrobial efficacy data against actual pathogens. No in vivo testing.

Questions This Raises

  • ?Does the insert maintain antimicrobial activity against keratitis-causing bacteria?
  • ?How does comfort and patient compliance compare to eye drops?
  • ?Can the insert be adapted for other antimicrobial peptides?

Trust & Context

Key Stat:
Leading cause Infectious keratitis is the leading cause of blindness worldwide, driving need for alternative AMP-based treatments
Evidence Grade:
In vitro formulation study. Strong drug delivery characterization but no antimicrobial or clinical efficacy data.
Study Age:
Published in 2020. Antimicrobial peptide formulations for ocular delivery continue to be developed.
Original Title:
Development and Characterization of a Novel Peptide-Loaded Antimicrobial Ocular Insert.
Published In:
Biomolecules, 10(5) (2020)
Database ID:
RPEP-05162

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is hLF 1-11?

It's an 11-amino acid antimicrobial peptide derived from the tip of human lactoferrin, a protein found in tears and breast milk. It can kill various bacteria and yeast, making it a promising alternative to antibiotics for eye infections.

Why use an insert instead of eye drops?

Eye drops require frequent application (often hourly for severe infections) and most of the drug washes away quickly. A dissolving insert stays on the eye surface and slowly releases the antimicrobial peptide, providing continuous treatment with better patient compliance.

Read More on RethinkPeptides

Cite This Study

RPEP-05162·https://rethinkpeptides.com/research/RPEP-05162

APA

Terreni, Eleonora; Burgalassi, Susi; Chetoni, Patrizia; Tampucci, Silvia; Zucchetti, Erica; Fais, Roberta; Ghelardi, Emilia; Lupetti, Antonella; Monti, Daniela. (2020). Development and Characterization of a Novel Peptide-Loaded Antimicrobial Ocular Insert.. Biomolecules, 10(5). https://doi.org/10.3390/biom10050664

MLA

Terreni, Eleonora, et al. "Development and Characterization of a Novel Peptide-Loaded Antimicrobial Ocular Insert.." Biomolecules, 2020. https://doi.org/10.3390/biom10050664

RethinkPeptides

RethinkPeptides Research Database. "Development and Characterization of a Novel Peptide-Loaded A..." RPEP-05162. Retrieved from https://rethinkpeptides.com/research/terreni-2020-development-and-characterization-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.